• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Oscar Health Inc.

    2/21/25 6:15:33 AM ET
    $OSCR
    Medical Specialities
    Health Care
    Get the next $OSCR alert in real time by email
    S-8 1 d936316ds8.htm S-8 S-8

    As filed with the United States Securities and Exchange Commission on February 20, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    OSCAR HEALTH, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   46-1315570
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)

    75 Varick Street, 5th Floor

    New York, New York 10013

    (646) 403-3677

    (Address, including zip code, of principal executive offices)

     

     

    OSCAR HEALTH, INC. 2021 INCENTIVE AWARD PLAN

    (Full title of the plan)

     

     

    Ranmali Bopitiya, Esq.

    Chief Legal Officer

    Oscar Health, Inc.

    75 Varick Street, 5th Floor

    New York, New York 10013

    (646) 403-3677

    (Name, address and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Keith L. Halverstam, Esq.

    Peter N. Handrinos, Esq.

    Latham & Watkins LLP

    1271 Avenue of the Americas

    New York, New York 10020

    (212) 906-1200

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    Explanatory Note

    This Registration Statement on Form S-8 is being filed by Oscar Health, Inc. (the “Company”) for the purpose of registering (i) an additional 5,349,287 shares of Class A common stock, par value $0.00001 per share (“Class A Common Stock”), that were automatically added on January 1, 2025 to the number of shares authorized for issuance under the Company’s 2021 Incentive Award Plan (the “2021 Plan”) pursuant to an “evergreen” provision, which allows for an annual increase in the number of shares of the Company’s common stock authorized for issuance thereunder; (ii) an additional 365,801 shares of Class A Common Stock that were issuable upon the exercise of stock option awards granted under the Company’s Amended and Restated 2012 Stock Incentive Plan that were canceled, forfeited or withheld to cover the exercise prices or taxes with respect to such options, and which became available for issuance under the 2021 Plan pursuant to the terms of the 2021 Plan; (iii) an additional 379,393 shares of Class A Common Stock that would have been issuable upon the vesting of restricted stock unit awards granted under the 2021 Plan, but that were canceled or forfeited prior to vesting, and as such again became available for issuance under the 2021 Plan pursuant to its terms; and (iv) an additional 4,000,000 shares of Class A Common Stock that may become issuable in the future under the 2021 Plan. The additional shares registered pursuant to the 2021 Plan are of the same class as other securities relating to the 2021 Plan for which Registration Statements on Form S-8 (Nos. 333-253817, 333-263057, 333-266835, 333-269979, 333-270890 and 333-277112) are effective.

    Pursuant to General Instruction E of Form S-8, the contents of the above-referenced prior registration statements are incorporated by reference herein to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

     

    Exhibit
    Number
      

    Description of Exhibit

     4.1    Amended and Restated Certificate of Incorporation of Oscar Health, Inc. (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40154) filed on March 8, 2021)
     4.2    Amended and Restated Bylaws of Oscar Health, Inc. (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40154) filed on March 8, 2021)
     5.1*    Opinion of Latham & Watkins LLP
    23.1*    Consent of PricewaterhouseCoopers LLP as to Oscar Health, Inc.
    23.2*    Consent of Latham & Watkins LLP (included in Exhibit 5.1)
    24.1*    Power of Attorney (included on the signature page of the Registration Statement)
    99.1    Oscar Health, Inc. 2021 Incentive Award Plan (incorporated herein by reference to Exhibit 10.4 to the Registrant’s Annual Report on Form 10-K (File No. 001-40154) filed on February 20, 2025)
    107.1*    Filing Fee Table

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on February 20, 2025.

     

    OSCAR HEALTH, INC.
    By:  

    /s/ Mark T. Bertolini

      Mark T. Bertolini
      Chief Executive Officer
      (Principal Executive Officer)

    SIGNATURES AND POWER OF ATTORNEY

    We, the undersigned officers and directors of Oscar Health, Inc., hereby severally constitute and appoint Mark T. Bertolini, R. Scott Blackley and Ranmali Bopitiya, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement (or any other Registration Statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Mark T. Bertolini

    Mark T. Bertolini

       Chief Executive Officer and Director (Principal Executive Officer)   February 20, 2025

    /s/ R. Scott Blackley

    R. Scott Blackley

      

    Chief Financial Officer

    (Principal Financial Officer)

      February 20, 2025

    /s/ Victoria Baltrus

    Victoria Baltrus

       Chief Accounting Officer (Principal Accounting Officer)   February 20, 2025


    /s/ Jeffery H. Boyd

    Jeffery H. Boyd

       Director   February 20, 2025

    /s/ William Gassen, III

    William Gassen, III

       Director   February 20, 2025

    /s/ Joshua Kushner

    Joshua Kushner

       Director   February 20, 2025

    /s/ Laura Lang

    Laura Lang

       Director   February 20, 2025

    /s/ David Plouffe

    David Plouffe

       Director   February 20, 2025

    /s/ Elbert O. Robinson, Jr.

    Elbert O. Robinson, Jr.

       Director   February 20, 2025

    /s/ Siddhartha Sankaran

    Siddhartha Sankaran

       Director   February 20, 2025

    /s/ Mario Schlosser

    Mario Schlosser

       Director   February 20, 2025

    /s/ Vanessa A. Wittman

    Vanessa A. Wittman

       Director   February 20, 2025
    Get the next $OSCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSCR

    DatePrice TargetRatingAnalyst
    3/13/2025$20.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/10/2024$12.00Underperform
    Jefferies
    11/6/2024$21.00 → $13.50Neutral → Underperform
    BofA Securities
    10/7/2024$23.00Neutral
    UBS
    6/26/2024$25.00Overweight
    Piper Sandler
    5/30/2024$28.00Outperform
    Robert W. Baird
    5/30/2024$25.00 → $21.00Buy → Neutral
    BofA Securities
    3/22/2024$20.00Outperform
    Raymond James
    More analyst ratings

    $OSCR
    Financials

    Live finance-specific insights

    See more
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Announces Fourth Quarter and Full Year 2024 Results; Introduces Full Year 2025 Outlook

      Reports Adjusted EBITDA and Net Income Profitability for the First Time in Company History For the year ended December 31, 2024: Total Revenue of $9.2 billion, a 56.5% increase year-over-year Medical Loss Ratio of 81.7%, a 10 bps increase year-over-year SG&A Expense Ratio of 19.1%, a 520 bps improvement year-over-year Net income attributable to Oscar of $25.4 million, or $0.10 of diluted earnings per share, a $296.2 million improvement year-over-year Adjusted EBITDA of $199.2 million, an improvement of $244.5 million year-over-year Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results

      2/4/25 4:05:00 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robinson Elbert O. Jr. sold $410,750 worth of shares (25,000 units at $16.43), decreasing direct ownership by 28% to 64,512 units (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      5/14/25 4:20:39 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Plouffe David

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:56 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Gassen William

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:43 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

      With new backing from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE:OSCR), Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMin

      3/5/25 2:13:00 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oscar Health Inc.

      SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 4:07:27 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Oscar Health Inc.

      SC 13G - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 1:28:35 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Oscar Health Inc.

      SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)

      11/13/24 9:24:55 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oscar Health downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Oscar Health from Overweight to Equal Weight and set a new price target of $16.00 from $20.00 previously

      3/13/25 8:18:37 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Jefferies initiated coverage on Oscar Health with a new price target

      Jefferies initiated coverage of Oscar Health with a rating of Underperform and set a new price target of $12.00

      12/10/24 7:59:30 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health downgraded by BofA Securities with a new price target

      BofA Securities downgraded Oscar Health from Neutral to Underperform and set a new price target of $13.50 from $21.00 previously

      11/6/24 7:54:31 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    SEC Filings

    See more
    • SEC Form 144 filed by Oscar Health Inc.

      144 - Oscar Health, Inc. (0001568651) (Subject)

      5/12/25 4:09:55 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Oscar Health Inc.

      10-Q - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 7:11:20 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 6:24:47 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thrive Partners Vii Growth Gp, Llc bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:33:02 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Co-Founder and Vice Chairman Kushner Joshua bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:29:47 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Director Thrive Partners Vii Growth Gp, Llc bought $5,444,343 worth of shares (344,522 units at $15.80) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/18/24 5:02:12 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Oscar Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York

      1/26/24 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Welcomes Two Healthcare Veterans to its Executive Leadership Team

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa

      9/6/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. Appoints Dr. Sean Martin, MD as New Chief Medical Officer

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built on a full stack technology platform, today announced that Dr. Sean Martin, MD has been appointed to serve as the company's new Chief Medical Officer, effective immediately. Dr. Martin joined Oscar in 2016 and during his tenure has provided clinical leadership across a number of core clinical functions, including enterprise affordability, medical management, market performance, population health, and behavioral health. In his new role, he will be responsible for implementing Oscar's clinical capabilities and enhancing the quality of care and outcomes for its members. "Dr. Martin is an avid champion of the us

      3/15/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care